Biocon has struck a deal that will see its GLP-1 diabetes and chronic weight management products commercialized in the Middle East region by partner Tabuk Pharmaceutical.
Biocon has struck a deal with Saudi firm Tabuk Pharmaceutical Manufacturing Company that will see the Indian company’s GLP-1 diabetes and chronic weight management products commercialized by Tabuk in “select countries” in the Middle East.
The agreements builds on an existing alliance between Biocon and Tabuk for generics, struck back in 2021 (see sidebar), which Biocon said at the time would pave the way for
Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.
